drugset / Trial / NCT01334034
Safety of NNC 0123-0000-0338 in Healthy Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body), and the pharmacodynamics (the effect of the investigated drug on the body) of NNC 0123-0000-0338 as tablets in healthy subjects.
Timeline
- Start
- 2011-04-11
- Primary completion
- 2011-09-16
- Completion
- 2011-09-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NNC 0123-0000-0338 | Unknown | — | Oral |
| Subject | insulin glargine | Protein / enzyme biologic | — | Subcutaneous |